

FINALISTS 2022

Licensing Deal Of The Year

This Scrip Award recognizes the licensing that are vital both in helping to keep pharma's pipelines replenished and in generating income for smaller firms.

Accord Healthcare with Myovant Sciences

to commercialize Orgovyx for advanced prostate cancer

Accord Healthcare entered into an exclusive license agreement with Myovant Sciences to commercialize relugolix for the treatment of advanced hormone-sensitive prostate cancer under the trade name Orgovyx in the European Economic Area, United Kingdom, Switzerland and Turkey, with the right of the first negotiation if Myovant decides to enter into licensing arrangements in countries in the Middle East, Africa and India. Prostate cancer is now the most frequently diagnosed cancer among men in Europe.

AstraZeneca and Ionis Pharmaceuticals

for the development and commercialization of eplontersen for TTR amyloidosis

In December 2021, AstraZeneca and Ionis Pharmaceuticals concluded a strategically important agreement enabling the global development and commercialization of eplontersen for of TTR amyloidosis, while enhancing the corporate strategies of both companies. AstraZeneca can build upon its rare disease expertise recently acquired through its purchase of Alexion, while the arrangement enables Ionis to participate in US commercial activities and grow its capabilities beyond a platform technology organisation.

GSK and Alector

for the development and commercialization of AL001 and AL101 for neurodegenerative diseases

GlaxoSmithKline and Alector, a clinical stage biotechnology company pioneering a novel therapeutic approach for the treatment of neurodegenerative diseases called immuno-neurology, entered into a strategic global collaboration and license agreement under which the parties will co-develop progranulin-elevating monoclonal antibodies, AL001 and AL101, for a range of neurodegenerative diseases, including frontotemporal dementia, amyotrophic lateral sclerosis, Parkinson's disease and Alzheimer's disease.

iTeos and GSK

for the development and commercialization of EOS-448 for solid tumors

In June 2021, iTeos and GSK announced a game-changing collaboration focused on the development and commercialization of EOS-448, an investigational anti-TIGIT monoclonal antibody. The alliance combines GSK's resources, commercial capabilities and broad immuno-oncology portfolio with an emerging, potentially differentiated IO candidate. For GSK, the alliance adds to its oncology portfolio, while iTeos received significant capital to fund a broad development plan and retained full co-commercialization rights in the US within a high-accountability environment.

RQ Biotechnology and AstraZeneca

for novel monoclonal antibodies targeting SARS-CoV-2

In April 2022, RQ Biotechnology and AstraZeneca entered into a worldwide exclusive licence covering a portfolio of novel monoclonal antibodies targeting SARS-CoV-2 initially identified from convalescent COVID-19 patients. Working in collaboration with Oxford University Innovation and LifeArc, RQ Bio selected the most promising leads based on a range of properties. For RQ Bio, this deal was transformational and has allowed it to emerge from stealth mode, while it reflected AstraZeneca's continued commitment to new approaches against COVID-19.

SCRIP AWARDS 2022

30 NOVEMBER 2022 · ROYAL LANCASTER, LONDON

Sunovion Pharmaceuticals and Otsuka Pharmaceutical

to jointly develop and commercialize ulotaront, non-racemic amisulpride, SEP-378614 and SEP-380135

The strategic alliance between Sunovion and Otsuka recognizes the great unmet need for novel neuropsychiatric medicines that are both effective and well tolerated. By leveraging Sunovion and Otsuka's complementary therapeutic area expertise and capabilities, the companies are fully exploring the potential of the compounds, accelerating development timelines to bring forward important novel treatments, and expanding the global scale beyond what would have been possible alone.

Winners are announced at the Awards ceremony and dinner on Wednesday 30th November at the Royal Lancaster Hotel, London.